Delineation of the Complement Receptor Type 2-C3d Complex by Site-Directed Mutagenesis and Molecular Docking

Journal of Molecular Biology

Volumn 404, Issue 4, 2010, Pages 697-710

  Shaw, Craig D ^a   Storek, Michael J ^b   Young, Kendra A ^c   Kovacs, James M ^c   Thurman, Joshua M ^c   Holers, V Michael ^b,c   Hannan, Jonathan P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Taligen Therapeutics   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Complement; Innate immunity; Regulators of complement activation; Short consensus repeats; Site directed mutagenesis

Indexed keywords

COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR C3D; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; INNATE IMMUNITY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

EID: 78549235728     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.10.005     Document Type: Article

References (63)

1. Kalli K.R., Ahearn J.M., Fearon D.T. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J. Immunol. 1991, 147:590-594.
2. r membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc. Natl Acad. Sci. USA 1984, 81:881-885.
3. Asokan R., Hua J., Young K.A., Gould H.J., Hannan J.P., Kraus D.M., et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-α: a potential role in systemic lupus erythematosus. J. Immunol. 2006, 177:383-394.
4. Delcayre A.X., Salas F., Mathur S., Kovats K., Lotz M., Lernhardt W. Epstein Barr virus complement C3d receptor is an interferon α receptor. EMBO J. 1991, 10:919-926.
5. Aubry J.P., Pochon S., Gauchat J.F., Nueda-Marin A., Holers V.M., Graber P., et al. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J. Immunol. 1994, 152:5806-5813.
6. Aubry J.P., Pochon S., Graber P., Jansen K.U., Bonnefoy J.Y. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992, 358:505-507.
7. Hibbert R.G., Teriete P., Grundy G.J., Beavil R.L., Reljic R., Holers V.M., et al. The structure of human CD23 and its interactions with IgE and CD21. J. Exp. Med. 2005, 202:751-760.
8. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl Acad. Sci. USA 1984, 81:4510-4514.
9. Nemerow G.R., Mold C., Schwend V.K., Tollefson V., Cooper N.R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 1987, 61:1416-1420.
10. Nemerow G.R., Wolfert R., McNaughton M.E., Cooper N.R. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J. Virol. 1985, 55:347-351.
11. Stano P., Williams V., Villani M., Cymbalyuk E.S., Qureshi A., Huang Y., et al. App1: an antiphagocytic protein that binds to complement receptors 3 and 2. J. Immunol. 2009, 182:84-91.
12. Hannan J.P., Szakonyi G., Asokan R., Chen X., Holers V.M. Complement receptor CR2/CD21 and CR2-C3d complexes. Structural Biology of the Complement System 2005, 143-160. Taylor & Francis Group, Boca Raton, FL. D. Morikis, J.D. Lambris (Eds.).
13. Carel J.C., Myones B.L., Frazier B., Holers V.M. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J. Biol. Chem. 1990, 265:12293-12299.
14. Guthridge J.M., Rakstang J.K., Young K.A., Hinshelwood J., Aslam M., Robertson A., et al. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry 2001, 40:5931-5941.
15. Hannan J.P., Young K.A., Guthridge J.M., Asokan R., Szakonyi G., Chen X.S., Holers V.M. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J. Mol. Biol. 2005, 346:845-858.
16. Lowell C.A., Klickstein L.B., Carter R.H., Mitchell J.A., Fearon D.T., Ahearn J.M. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J. Exp. Med. 1989, 170:1931-1946.
17. Molina H., Brenner C., Jacobi S., Gorka J., Carel J.C., Kinoshita T., Holers V.M. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J. Biol. Chem. 1991, 266:12173-12179.
18. Molina H., Perkins S.J., Guthridge J., Gorka J., Kinoshita T., Holers V.M. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules. J. Immunol. 1995, 154:5426-5435.
19. Sarrias M.R., Franchini S., Canziani G., Argyropoulos E., Moore W.T., Sahu A., Lambris J.D. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J. Immunol. 2001, 167:1490-1499.
20. Young K.A., Chen X.S., Holers V.M., Hannan J.P. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). J. Biol. Chem. 2007, 282:36614-36625.
21. Young K.A., Herbert A.P., Barlow P.N., Holers V.M., Hannan J.P. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J. Virol. 2008, 82:11217-11227.
22. Fang Y., Xu C., Fu Y.X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 1998, 160:5273-5279.
23. Szakonyi G., Guthridge J.M., Li D., Young K., Holers V.M., Chen X.S. Structure of complement receptor 2 in complex with its C3d ligand. Science 2001, 292:1725-1728.
24. Prota A.E., Sage D.R., Stehle T., Fingeroth J.D. The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding. Proc. Natl Acad. Sci. USA 2002, 99:10641-10646.
25. Nagar B., Jones R.G., Diefenbach R.J., Isenman D.E., Rini J.M. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 1998, 280:1277-1281.
26. Martin D.R., Yuryev A., Kalli K.R., Fearon D.T., Ahearn J.M. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J. Exp. Med. 1991, 174:1299-1311.
27. Kovacs J.M., Hannan J.P., Eisenmesser E.Z., Holers V.M. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J. Biol. Chem. 2009, 284:9513-9520.
28. Gilbert H.E., Asokan R., Holers V.M., Perkins S.J. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. J. Mol. Biol. 2006, 362:1132-1147.
29. Gilbert H.E., Eaton J.T., Hannan J.P., Holers V.M., Perkins S.J. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. J. Mol. Biol. 2005, 346:859-873.
30. Li K., Okemefuna A.I., Gor J., Hannan J.P., Asokan R., Holers V.M., Perkins S.J. Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2. J. Mol. Biol. 2008, 384:137-150.
31. Clemenza L., Isenman D.E. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21). J. Immunol. 2000, 165:3839-3848.
32. Isenman D.E., Leung E., Mackay J.D., Bagby S., van den Elsen J.M.H. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure. J. Immunol. 2010, 184:1946-1955.
33. Morikis D., Lambris J.D. The electrostatic nature of C3d-complement receptor 2 association. J. Immunol. 2004, 172:7537-7547.
34. Zhang L., Mallik B., Morikis D. Immunophysical exploration of C3d-CR2(CCP1-2) interaction using molecular dynamics and electrostatics. J. Mol. Biol. 2007, 369:567-583.
35. Cheung A.S., Kieslich C.A., Yang J.F., Morikis D. Solvation effects in calculated electrostatic association free energies for the C3d-CR2 complex and comparison with experimental data. Biopolymers 2010, 93:509-519.
36. De Vries S.J., van Dijk M., Bonvin A. The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 2010, 5:883-897.
37. Dominguez C., Boelens R., Bonvin A.M. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 2003, 125:1731-1737.
38. van Zelm M.C., Reisli I., van der Burg M., Castano D., van Noesel C.J., van Tol M.J., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 2006, 354:1901-1912.
39. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001, 15:775-785.
40. Douglas K.B., Windels D.C., Zhao J., Gadeliya A.V., Wu H., Kaufman K.M., et al. Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing. Genes Immun. 2009, 10:457-469.
41. Prodeus A.P., Goerg S., Shen L.M., Pozdnyakova O.O., Chu L., Alicot E.M., et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998, 9:721-731.
42. Del Nagro C.J., Kolla R.V., Rickert R.C. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J. Immunol. 2005, 175:5379-5389.
43. Kaya Z., Afanasyeva M., Wang Y., Dohmen K.M., Schlichting J., Tretter T., et al. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2001, 2:739-745.
44. Kuhn K.A., Cozine C.L., Tomooka B., Robinson W.H., Holers V.M. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol. Immunol. 2008, 45:2808-2819.
45. Kovacs J.M., Hannan J.P., Eisenmesser E.Z., Holers V.M. Biophysical investigations of complement receptor 2 (CD21, CR2) ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J. Biol. Chem. 2010, 285:27251-27258.
46. Toapanta F.R., DeAlmeida D.R., Dunn M.D., Ross T.M. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2. Immunol. Lett. 2010, 129:32-38.
47. van Dijk A.D., de Vries S.J., Dominguez C., Chen H., Zhou H.X., Bonvin A.M. Data-driven docking: HADDOCK's adventures in CAPRI. Proteins 2005, 60:232-238.
48. De Vries S.J., van Dijk A.D., Krzeminski M., van Dijk M., Thureau A., Hsu V., et al. HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 2007, 69:726-733.
49. Storek M.J., Holers V.M., Shaw C.D., Young K.A., Kovacs J.M., Thurman J.M., Hannan J.P. Characterizing the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular modeling. Mol. Immunol. 2010, 47:2258.
50. Lambris J.D., Dobson N.J., Ross G.D. Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for β1H globulin. J. Exp. Med. 1980, 152:1625-1644.
51. Lambris J.D., Ross G.D. Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres. J. Immunol. 1982, 128:186-189.
52. Lambris J.D. The multifunctional role of C3, the third component of complement. Immunol. Today 1988, 9:387-393.
53. Ricklin D., Tzekou A., Garcia B.L., Hammel M., McWhorter W.J., Sfyroera G., et al. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 2009, 183:2565-2574.
54. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
55. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213-216.
56. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006, 444:217-220.
57. Janssen B.J., Gros P. Structural insights into the central complement component C3. Mol. Immunol. 2007, 44:3-10.
58. Burman J.D., Leung E., Atkins K.L., O'Seaghdha M.N., Lango L., Bernado P., et al. Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus. J. Biol. Chem. 2008, 283:17579-17593.
59. Upadhyay A., Burman J.D., Clark E.A., Leung E., Isenman D.E., van den Elsen J.M., Bagby S. Structure-function analysis of the C3 binding region of Staphylococcus aureus immune subversion protein Sbi. J. Biol. Chem. 2008, 283:22113-22120.
60. Hammel M., Sfyroera G., Pyrpassopoulos S., Ricklin D., Ramyar K.X., Pop M., et al. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 2007, 282:30051-30061.
61. Ricklin D., Ricklin-Lichtsteiner S.K., Markiewski M.M., Geisbrecht B.V., Lambris J.D. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J. Immunol. 2008, 181:7463-7467.
62. Hammel M., Sfyroera G., Ricklin D., Magotti P., Lambris J.D., Geisbrecht B.V. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 2007, 8:430-437.
63. Szakonyi G., Klein M.G., Hannan J.P., Young K.A., Ma R.Z., Asokan R., et al. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat. Struct. Mol. Biol. 2006, 13:996-1001.